Soft Pulse Antithrombotic Capsule Treatment Of Chronic Cerebral Insufficiency Clinical Studies

Objective:To observe the clinical effection of Roumaikangshuan capsules on chronic cerebral circulation insufficiency(CCCI). Methodes: 120 patients of CCCI were randomly divided into two groups.60 patients of CCCI in the treatment group were treated with Roumaikangshuan capsules 4 pills twice a day.At the same time,Yuzunaoluo team give Roumaikangshuan capsules only;Ganshenyinxu team were treated with Liuweidihuangwan 10 pills three times a day;Qixuxueyu team were treated with Huangqi 30g a day;Ganyangshangkang team were treated with Tianma 15g,Jühua 15g a day. The other 60 patients of CCCI in the control group were treated with Aspirin 50-100mg once a day,Nimodipine 20mg three times a day. The course of treatment was 3 months .And observing clinical symptom, C-reactive protein(CRP) index, Thrombcxane B2(TXB2) and 6- Ketone-Prostaglandin F1a(6-Keto-PGF1a) index,TCD index, Hemorheologic index,the morbidity of TIA and CI,clinical healing effection in pre and post treatment diversity time. Reexamined a part of patients whose course of treatment were over one year. Results:3 months and 1 year later,the clinical symptom of the treatment group was improved better than the control group after treating(P<0.05), the healing and obviousness effective rate ,total effective rate in the treatment group was 33.4% , 71.7% and 45.8% , 79.1% respectively,and were significantly higher than those that was11.7%,48.4% and 18.5%,58.1% in the control group (P<0.05);the morbidity of TIA and CI in the treatment group was 1.7%,1.7% and 8.3%,4.2% respectively, and were significantly lower than those that was3.3%,3.3% and 14.8%,11.1% in the control group (P<0.05);the TXB2 index of the treatment group was significantly lower than the control group(P<0.05),the 6-Keto-PGF1a index of the treatment group was significantly higher than the control group(P < 0.05),the TXB2/6-Keto-PGF1a of the treatment group was significantly lower than the control group(P<0.01);the CRP index of the treatment group was significantly lower than the control group(P<0.05); the TCD index(PI) of both groups were higher than before,but the treatment group was increased slowly than the control group;the Hemorheologic index of the treatment group was significantly lower than the control group(P<0.05). In the treatment group , no case experienced side reactions,the safe indexs including clotting function,renal function and so on did not change significantly pre and post treatment.Conclusion: Roumaikangshuan capsules is not only safe and has a good clinical effection on CCCI,but also can improve the clinical symptom,reduce the morbidity of TIA and CI,fall off the CRP index and TXB2/6-keto-PGF1a index obviously,made PI and Hemorheologic index low.